Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Pricing Debate Will Carry Over To 2020

Executive Summary

An eventful year for sweeping drug pricing legislative proposals in the US will end with enactment of a long-standing carryover proposal – new procedures intended to address perceived abuses of the REMS process – but nothing more substantial for the drug industry.

You may also be interested in...



Bill To Lower Pay Of Out-Of-Network Physicians, Costs Delayed To 2020

A bill meant to stop out-of-network "surprise billing" may have stalled but is likely to make a reappearance when Congress reconvenes next year according to lawmakers and experts. Despite support in key Senate and House committees, the bill hit a wall when lawmakers introduced an alternative version in the House Ways and Means Committee late in the legislative session.

Mylan/Biocon’s Insulin Glargine Would Get A Respite Under US Budget Legislation

Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.

CREATES Act Approaches Finish Line But Legislation May Fail To Launch

Broad bipartisan support and billions in projected savings mean that bill may finally pass. But whether it will work as intended to improve generic access to market remains as questionable as ever.

 

Topics

UsernamePublicRestriction

Register

PS141414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel